Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety

Coronavirus disease (COVID-19) pandemic has been a global disease burden. It has affected more than sixteen million people in the world within seven months of its first outbreak in Wuhan. Different treatment modalities, therapeutic and prophylactic agents for its therapy are underway. Until the prov...

Descripción completa

Detalles Bibliográficos
Autores principales: Khadka, Sitaram, Shrestha, Dhan Bahadur, Budhathoki, Pravash, Rawal, Era
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450277/
https://www.ncbi.nlm.nih.gov/pubmed/32904117
http://dx.doi.org/10.2147/CPAA.S269156
_version_ 1783574783402704896
author Khadka, Sitaram
Shrestha, Dhan Bahadur
Budhathoki, Pravash
Rawal, Era
author_facet Khadka, Sitaram
Shrestha, Dhan Bahadur
Budhathoki, Pravash
Rawal, Era
author_sort Khadka, Sitaram
collection PubMed
description Coronavirus disease (COVID-19) pandemic has been a global disease burden. It has affected more than sixteen million people in the world within seven months of its first outbreak in Wuhan. Different treatment modalities, therapeutic and prophylactic agents for its therapy are underway. Until the proven therapy gets available, repurposing of drugs is a better way out. Hydroxychloroquine (HCQ) has been a potential recourse of treatment in this regard for COVID-19 management. As different episodes of cardiac adverse events of HCQ are reported, safety concerns are now a prime objective. The risk-benefit analysis is mandatory to address rational drug therapy even in such a global health crisis. In this article, we want to evaluate the safety and efficacy of HCQ in COVID-19 management.
format Online
Article
Text
id pubmed-7450277
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74502772020-09-04 Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety Khadka, Sitaram Shrestha, Dhan Bahadur Budhathoki, Pravash Rawal, Era Clin Pharmacol Commentary Coronavirus disease (COVID-19) pandemic has been a global disease burden. It has affected more than sixteen million people in the world within seven months of its first outbreak in Wuhan. Different treatment modalities, therapeutic and prophylactic agents for its therapy are underway. Until the proven therapy gets available, repurposing of drugs is a better way out. Hydroxychloroquine (HCQ) has been a potential recourse of treatment in this regard for COVID-19 management. As different episodes of cardiac adverse events of HCQ are reported, safety concerns are now a prime objective. The risk-benefit analysis is mandatory to address rational drug therapy even in such a global health crisis. In this article, we want to evaluate the safety and efficacy of HCQ in COVID-19 management. Dove 2020-08-17 /pmc/articles/PMC7450277/ /pubmed/32904117 http://dx.doi.org/10.2147/CPAA.S269156 Text en © 2020 Khadka et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Commentary
Khadka, Sitaram
Shrestha, Dhan Bahadur
Budhathoki, Pravash
Rawal, Era
Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
title Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
title_full Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
title_fullStr Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
title_full_unstemmed Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
title_short Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
title_sort hydroxychloroquine in covid-19: the study points to premature decisions on efficacy while bells ringing for safety
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450277/
https://www.ncbi.nlm.nih.gov/pubmed/32904117
http://dx.doi.org/10.2147/CPAA.S269156
work_keys_str_mv AT khadkasitaram hydroxychloroquineincovid19thestudypointstoprematuredecisionsonefficacywhilebellsringingforsafety
AT shresthadhanbahadur hydroxychloroquineincovid19thestudypointstoprematuredecisionsonefficacywhilebellsringingforsafety
AT budhathokipravash hydroxychloroquineincovid19thestudypointstoprematuredecisionsonefficacywhilebellsringingforsafety
AT rawalera hydroxychloroquineincovid19thestudypointstoprematuredecisionsonefficacywhilebellsringingforsafety

Ejemplares similares